Immunobiology and Immunotherapy of Cancer Metastases Ten-Year Studies in an Animal Model Resulting the Design of an Immunotherapy Procedure now under Clinical Testing
Datos Bibliográficos
| ID | 11935440 |
|---|---|
| Autores | Volker Schirrmacher (0000-0003-1253-9145, German Cancer Research Center, autor de correspondencia) |
| Año | 1989 |
| Volumen | 14 |
| Número | 3 |
| Páginas | 291-303 |
| Fecha de publicación | 1989-09-01 |
| Peer Reviewed | Sí |
| Open Access | No |
| Tipo | ARTICLE |
| Revista | Interdisciplinary Science Reviews (JOURNAL) |
| Identificadores de la revista | ISSN: 0308-0188 • E-ISSN: 1743-2790 |
| Editorial | Taylor & Francis (PUBLISHER • GB) |
| DOI | 10.1179/isr.1989.14.3.291 |
| OpenAlex | W1978032735 |
| Idioma | EN |
| Referencias citadas | 34 |
Failure of cancer therapy can most often be attributed to metastasis, which changes a localised disease into a systemic one. Animal models have contributed to improved understanding of metastasis formation, dissemination and treatment, and in this review immunological findings from the highly metastatic murine ESb lymphoma model are presented. Insights gained from this research can be applied to the design of new immunotherapy protocols for the treatment of many human cancers. The development and application of active specific immunotherapy (ASI) are described
Cancer · Cancer Immunotherapy · Clinical trial · Disease · Immunotherapy · Lymphoma · Metastasis · Cancer Genomics and Diagnostics · Cancer Immunotherapy and Biomarkers · Immunotherapy and Immune Responses · Medicine · Immunology · Internal Medicine
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |